Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q6NT55

UPID:
CP4FN_HUMAN

ALTERNATIVE NAMES:
Cytochrome P450 4F22

ALTERNATIVE UPACC:
Q6NT55; Q8N8H4

BACKGROUND:
The protein Ultra-long-chain fatty acid omega-hydroxylase, also known as Cytochrome P450 4F22, is crucial for the omega-hydroxylation of ultra-long-chain fatty acyls in ceramide biosynthesis. This process is vital for maintaining the skin's barrier function through the production of specific lipid components.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in congenital ichthyosis, exploring Cytochrome P450 4F22's function offers a promising avenue for developing targeted therapies for this and potentially other skin conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.